This Drug Combination for Eli Lilly Generated Significantly More Weight Loss Than Just Zepbound, but Discontinuation Rates Were Also Far Higher. Here's What This Could Mean for the Stock

Eli Lilly's new drug combination showed promising weight loss results but also had higher discontinuation rates compared to its current GLP-1 drugs.

Want to stay up to date with the world events at sea or at home?

Explore Navvyx News - the best News app for seafarers.